Jeffrey Cohen, MD, MPH: Treatment of Psoriasis in High-impact Sites

Dr. Cohen discusses the best biologics for treating psoriasis of the scalp, intertriginous areas, genitals, nails, and palms and soles of the feet.

MORE COVERAGE FROM THE 2025 AAD INNOVATION ACADEMY MEETING

Dr. Hsiao discusses efficacy and safety of dual biologic treatment in patients with severe and recalcitrant HS, as well as commonly used biologic combinations that

Dr. Bhatia discusses upcoming topical therapies while honoring the utility and usefulness of older topical treatments.

Dr. Harper discusses results from head-to-head studies comparing new and existing oral rosacea treatments and navigating the difficulties of treating neurogenic rosacea.

Dr. Liu discusses new and emerging topical therapies for psoriasis and the continued value of topical therapies in psoriasis treatment.

Dr. Murina discusses using oral psoriasis drugs as a stepping stone to introduce patients with psoriasis to systemic therapies.

Dr. Lebwohl discusses navigating psoriasis treatment in elderly patients, including reduced renal function, increased predisposition to malignancies, and financial burdens of treatment access.

Dr. Daveluy discusses an exciting new project to uncover insights into HS disease patterns through analysis with artificial intelligence.

Dr. Elbuluk discusses unique considerations pertaining to inflammatory skin diseases in patients with skin of color.

Dr. Khattri discusses emerging psoriatic arthritis treatments on the horizon, including deucravacitinib, zasocitinib, and icotrokinra.

Dr. Song discusses the specific utility of interleukin (IL)-17 inhibitors when treating psoriatic disease, including in biologic-experienced patients, psoriasis in special sites, and psoriatic arthritis.

Dr. Bhatia reviews exciting new developments in dermatology technology, including a full-body dermoscopic robot, autologous cell transplants for wound healing, and stem cell banking for

The AAD © Brand and Content are created by the American Academy of Dermatology “All rights reserved.” Any reproduction or republication is strictly prohibited without prior authorization.

The content of the 2025 AAD Innovation Academy Meeting (the “Content”) is copyrighted by the American Academy of Dermatology (“AAD”). The Works, JCADTV Coverage from the 2025 AAD Innovation Academy Meeting, are made up of coverage interviews and summaries and are created from the Content of the AAD under a license between the AAD and Matrix Medical Communications (“MATRIX MEDICAL COMMUNICATIONS”), and MATRIX MEDICAL COMMUNICATIONS is solely responsible for their content. The license of any content by the AAD does not constitute or imply endorsement of any company or its goods, services, or written work products, and the AAD is not responsible for any errors or omissions in the translation or reproduction of the content.